BRIACELL THERAPEUTICS CORP. Increase (Decrease) in Other Accounts Payable and Accrued Liabilities
BRIACELL THERAPEUTICS CORP. (BCTX) reported Increase (Decrease) in Other Accounts Payable and Accrued Liabilities of $721.77 thousand for the 9-month period ending 2026-04-30, per its 10-Q filed 2026-06-09.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities · last filed 2026-06-09
- BRIACELL THERAPEUTICS CORP. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2026-04-30 was $110.16K, a 86.63% decline year-over-year.
- BRIACELL THERAPEUTICS CORP. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2026-01-31 was $117.05K.
- BRIACELL THERAPEUTICS CORP. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2025-10-31 was $494.57K, a 6.52% increase year-over-year.
- BRIACELL THERAPEUTICS CORP. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2025-07-31 was -$357.14K.
- BRIACELL THERAPEUTICS CORP. increase (decrease) in other accounts payable and accrued liabilities for fiscal 2025 was $753.91K.
- BRIACELL THERAPEUTICS CORP. increase (decrease) in other accounts payable and accrued liabilities for fiscal 2024 was -$387.34K, a 293.76% decline from fiscal 2023.
- BRIACELL THERAPEUTICS CORP. increase (decrease) in other accounts payable and accrued liabilities for fiscal 2023 was $199.91K, a 47.94% increase from fiscal 2022.
- BRIACELL THERAPEUTICS CORP. increase (decrease) in other accounts payable and accrued liabilities for fiscal 2022 was $135.13K.
| Period end | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-04-30 | $110.16K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-06-09 | $227.20K derived: sum of 2 quarters · filed 2026-06-09 | $721.77K 10-Q · filed 2026-06-09 | $364.63K derived: sum of 4 quarters · filed 2026-06-09 |
| 2026-01-31 | $117.05K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-03-10 | $611.62K 10-Q · filed 2026-03-10 | $254.47K derived: sum of 3 quarters · filed 2026-03-10 | $1.08M derived: sum of 4 quarters · filed 2026-06-09 |
| 2025-10-31 | $494.57K 10-Q · filed 2025-12-11 | $137.43K derived: sum of 2 quarters · filed 2025-12-11 | $961.26K derived: sum of 3 quarters · filed 2026-06-09 | $784.19K derived: sum of 4 quarters · filed 2026-06-09 |
| 2025-07-31 | -$357.14K derived: 10-K 12 month − 10-Q 9 month · filed 2025-10-16 | $466.69K derived: sum of 2 quarters · filed 2026-06-09 | $289.62K derived: sum of 3 quarters · filed 2026-06-09 | $753.91K 10-K · filed 2025-10-16 |
| 2025-04-30 | $823.83K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-06-09 | $646.76K derived: sum of 2 quarters · filed 2026-06-09 | $1.11M 10-Q · filed 2026-06-09 | $1.07M derived: sum of 4 quarters · filed 2026-06-09 |
| 2025-01-31 | -$177.07K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-03-10 | $287.22K 10-Q · filed 2026-03-10 | $242.24K derived: sum of 3 quarters · filed 2026-03-10 | $364.73K derived: sum of 4 quarters · filed 2026-03-10 |
| 2024-10-31 | $464.29K 10-Q · filed 2025-12-11 | $419.31K derived: sum of 2 quarters · filed 2025-12-11 | $541.80K derived: sum of 3 quarters · filed 2025-12-11 | $142.08K derived: sum of 4 quarters · filed 2025-12-11 |
| 2024-07-31 | -$44.98K derived: 10-K 12 month − 10-Q 9 month · filed 2025-10-16 | $77.51K derived: sum of 2 quarters · filed 2025-10-16 | -$322.21K derived: sum of 3 quarters · filed 2025-10-16 | -$387.34K 10-K · filed 2025-10-16 |
| 2024-04-30 | $122.49K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-06-16 | -$277.23K derived: sum of 2 quarters · filed 2025-06-16 | -$342.36K 10-Q · filed 2025-06-16 | -$52.48K derived: sum of 4 quarters · filed 2025-06-16 |
| 2024-01-31 | -$399.72K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-03-12 | -$464.85K 10-Q · filed 2025-03-12 | -$174.97K derived: sum of 3 quarters · filed 2025-03-12 | $124.91K derived: sum of 4 quarters · filed 2025-03-12 |
| 2023-10-31 | -$65.13K 10-Q · filed 2024-12-16 | $224.75K derived: sum of 2 quarters · filed 2024-12-16 | $524.63K derived: sum of 3 quarters · filed 2024-12-16 | $430.29K derived: sum of 4 quarters · filed 2024-12-16 |
| 2023-07-31 | $289.88K derived: 10-K 12 month − 10-Q 9 month · filed 2024-10-29 | $589.76K derived: sum of 2 quarters · filed 2024-10-29 | $495.42K derived: sum of 3 quarters · filed 2024-10-29 | $199.91K 10-K · filed 2024-10-29 |
| 2023-04-30 | $299.88K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-06-14 | $205.54K derived: sum of 2 quarters · filed 2024-06-14 | -$89.97K 10-Q · filed 2024-06-14 | $242.61K derived: sum of 4 quarters · filed 2024-06-14 |
| 2023-01-31 | -$94.34K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-03-18 | -$389.85K 10-Q · filed 2024-03-18 | -$57.27K derived: sum of 3 quarters · filed 2024-03-18 | $11.07K derived: sum of 4 quarters · filed 2024-03-18 |
| 2022-10-31 | -$295.50K 10-Q · filed 2023-12-14 | $37.07K derived: sum of 2 quarters · filed 2023-12-14 | $105.41K derived: sum of 3 quarters · filed 2023-12-14 | -$5.61K derived: sum of 4 quarters · filed 2023-12-14 |
| 2022-07-31 | $332.58K derived: 10-K 12 month − 10-Q 9 month · filed 2023-10-25 | $400.92K derived: sum of 2 quarters · filed 2023-10-25 | $289.89K derived: sum of 3 quarters · filed 2023-10-25 | $135.13K 10-K · filed 2023-10-25 |
| 2022-04-30 | $68.34K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-06-14 | -$42.69K derived: sum of 2 quarters · filed 2023-06-14 | -$197.45K 10-Q · filed 2023-06-14 | |
| 2022-01-31 | -$111.03K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-03-16 | -$265.79K 10-Q · filed 2023-03-16 | ||
| 2021-10-31 | -$154.76K 10-Q · filed 2022-12-14 | |||
| 2021-07-31 | -$785.40K 10-K · filed 2022-10-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |